

February, 2009

Columbus CCOP  
1335 Dublin Road, Suite  
124-A  
Columbus, OH 43215

Phone: 614-488-2118  
Fax: 614-488-2647  
[www.columbusccop.org](http://www.columbusccop.org)

# CCOP NEWS



A Community of Caring in Cancer Research

## Columbus Community Clinical Oncology Program

### CANCER CONTROL TRIALS ARE IMPORTANT!

NCI Funding received by the Columbus Community Clinical Oncology Program requires accrual of a minimal number of cancer control credits. Cancer control accruals received year to date are less than 20 credits. The Columbus CCOP is required to accrue a minimum 50 cancer control credits to satisfy our standing with the NCI. Our goal, as established by the NCI, is 110 credits this year, leaving just 4 months to close a gap of over 90 credits. All CCOP members are asked to continue an intense focus of screening new patients to determine if they are eligible for cancer control studies. Below is a list of cancer control trials currently available through the Columbus CCOP. Thank you for your support in ensuring that we remain one of the top CCOPs!

ECOG E2Z04	Quality of life in Younger Breast Cancer Survivors
ECOG E5597	Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage 1 Non-Small Cell Lung Cancer
HLMCC 0501	Stress Management Therapy for Patients Undergoing Chemotherapy. Open for hispanic patients only.
NCCTG N04CA	Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study
NCCTG N07C2	The Use of Wisconsin Ginseng (panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
SWOG S0424	Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
<b>NEW!</b> <b>SWOG S0702</b>	A prospective observational multicenter cohort study to assess the incidence of osteonecrosis of the jaw in patients with bone metastases starting zoledronic acid.
URCC 07079	Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind, Placebo-Controlled Clinical Trial
URCC U1105	Prevention of Delayed Nausea - A Phase III Double-Blind Placebo-Controlled Clinical Trial
URCC U1701	Dyspnea in Cancer Patients

**2009  
ASCO  
REVIEW  
JUNE 18, 2009**

### MARK YOUR CALENDAR!

The Columbus CCOP, in joint sponsorship with Riverside Methodist Hospital, presents the 2009 ASCO Review. Plan to join your colleagues to hear 8 nationally recognized speakers summarize the highlights of the annual ASCO Meeting on June, 18, 2009.

Registration will be open in March.



**OUR MISSION:** The Columbus Community Clinical Oncology Program (Columbus CCOP) strives to deliver state-of-the-art cancer care to patients in their communities through clinical trials. This allows individuals to remain in their own neighborhoods while receiving the latest and best in cancer screenings, diagnostic care and treatment plans.

Please send newsletter comments to [steveo@columbusccop.org](mailto:steveo@columbusccop.org)



## MARK YOUR CALENDAR

- **April 2, 2009: Update on Melanoma.** Please note the date of this event has moved to April 2, 2009. Dr. John Kirkwood will return to present the latest updates on Melanoma at the Brio Tuscan Grille at Polaris. This will be an evening CME program starting at 6:30 PM. Registration forms can be found at <http://www.columbusccop.org/news/index.html>
- **June 18, 2009:** Mark your calendar for the **2009 ASCO Review**. The annual Columbus CCOP 2009 ASCO Review will once again feature nationally recognized speakers who will summarize the highlights of the annual ASCO Meeting. This has been a highly regarded regional CME event since 2000 and you will not want to miss it! Registration will be available in March.



**2009  
ASCO  
REVIEW  
JUNE 18, 2009**

## NCI TRIAL NEWS

The following trials are now open for accrual:

**CALGB 40503:** Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy plus Bevacizumab (NSC-704865; IND 7921) for Women with Hormone Receptor-Positive Advanced Breast Cancer.

**NSABP B-43:** A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.

**SWOG S0702:** This is a prospective observational multicenter cohort **cancer control** study to assess the incidence of osteonecrosis of the jaw in patients with bone metastases starting zoledronic acid.

**[Please remember to consider cancer control protocols found in the Columbus CCOP protocol book or at \[www.columbusccop.org\]\(http://www.columbusccop.org\).](#)**

Protocols and consent forms can be found at [www.columbusccop.org](http://www.columbusccop.org)

## INDUSTRY TRIAL NEWS

The following industry trial is open for accrual:

- **NSABP B-41:** This is a randomized phase III trial of neoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following AC accompanied by correlative science studies to identify predictors of pathologic complete response.

Protocol and consent forms can be found at [www.columbusccop.org](http://www.columbusccop.org).



## KUEBLER'S



I hope you are all doing well. Your CCOP central office remains quite active as the weather thaws. Presently, we are working on the annual report to be filed with the NCI at the end of March. This details what we have done over the first 9 months of the NCI's fiscal year in comparison to where we were at this time last year. It also includes our budget requests for the upcoming year ... the last one for the present grant.

In fact, we are waiting for the CCOP RFA to be released from NCI so we can get started on our competitive renewal grant due this summer. Of course, we are already working on this document, with discussions about what we will include, how we will highlight our successes, and how we will explain areas that have not been successful (reference cancer control accrual this year). I think we have a very strong CCOP, and can make the case that we deserve another 5 years of funding, don't you? This grant will be placed before the grant review committee next November. Having served a number of times on this body, I can tell you that each grant is rigorously reviewed. We will get our priority score at the end of this year and likely find out if we scored in the fundable range next spring. A long process, but designed to select only the best grant requests for funding. The competition is stiff since all the original CCOPs that have been continuously funded, and therefore know the process well and write good grants, are in our renewal year. I am not sure if you realize that we are one of the original 19 CCOPs funded since the inception of the CCOP program in the early 1980's. This says it all, don't you think?

We are actively recruiting one or two assistant CCOP PIs. No ... I don't intend to retire, but I serve at the best of the board, and as I age, it seems wise to begin working on an orderly succession. This is also an issue for a number of other CCOPs across the country with the graying of experienced PIs. I will have more to say about this soon.

We continue to look for new trials and try to select the best released each month to present to our ad hoc reviewers for their opinions. If you are tapped to do a review of a proposed protocol, I hope you will take the necessary time to let us know if the study seems compatible in our community and asks worthwhile scientific questions. We always appreciate your efforts!

Have a good month, and think CANCER CONTROL!

*Phil Kuebler*

## Welcome



Please welcome Dr Vivek Abhyankar to the Columbus CCOP. Dr. Abhyankar is affiliated with Marietta Memorial Hospital and specializes in internal medicine, hematology and medical oncology. He is a graduate of Albany Medical College, New York. He completed his residency and fellowship at The Ohio State University. Dr Abhyankar has been recognized for his achievements multiple times including the ASCO Young Investigator Award and ASCO Merit Award.

## Guess Who?



Guess which research nurse is engaged to be married? A Columbus CCOP nurse recently became engaged and is busy making plans for the big day. More to come at a later date ...



## **DID YOU KNOW?**

New and available for the first time is the “Physical Activity Guidelines for Americans”.

Dr. Richard Troiano is an epidemiologist in the Risk Factor Monitoring and Methods Branch of NCI’s Division of Cancer Control and Population Sciences (DCCPS). In 2006, he was detailed to the U.S. Department of Health and Human Services (HHS) Office of Disease Prevention and Health Promotion to help develop the first-ever federal Physical Activity Guide for Americans, which was released in the fall of 2008.



The goals of the Physical Activity Guide for Americans are to provide information and guidance on the types and amounts of physical activity that provide substantial health benefits for Americans aged 6 years and older. The main idea behind the *Guidelines* is that regular physical activity can produce long-term health benefits.

Take a look at this valuable information at <http://www.health.gov/paguidelines/>



## **YOU CAN HELP! COLUMBUS CCOP DONATIONS**

The Columbus Community Clinical Oncology Program is a community based non-profit organization with a mission to deliver state-of-the-art cancer care to patients in their communities through clinical trials. This allows individuals to remain in their own neighborhoods while receiving the latest and best in cancer screenings, diagnostic care and treatment plans. We have grown into a consortium of 15 member hospitals with about 100 participating physicians, 35 nurses and many other healthcare professionals. We have remained one of the top CCOPs in the United States because of the efforts of each of them. Our members live and work throughout central and southeast Ohio and are dedicated to serving their communities.

The Columbus CCOP has provided medical education not only for its members, but physicians, nurses and pharmacists from across Ohio. We have delivered the most current information on cancer diagnosis, treatment and control for over 20 years. We remain committed to provide various education programs aimed at benefiting communities across Ohio and its neighbors.

Of course it costs money to keep the Columbus CCOP running effectively. The majority of our funding is provided by a grant from the National Cancer Institute. However, did you know that we also accept, and are extremely grateful for, private donations from individuals? You can help support the Columbus CCOP in a couple different ways:

- You can fill out a simple donation form and mail your check to the address shown at the bottom of the form. Go to <http://www.columbusccop.org/news/nletters/CCOP%20Donation%20Form.pdf>.
- You can make a credit card donation through the Columbus Foundation at [www.columbusfoundation.org](http://www.columbusfoundation.org). Users should register for a username and password prior to logging in. On the Columbus Foundation Home Page select PowerPhilanthropy Login. Click on Create a Username and Password. Click on Sign-up form under Public Users. Complete the form and click on Submit. Your user ID and password will be sent to your email. To donate to the Columbus CCOP select PowerPhilanthropy Login at the top of the page. Enter the user name and password that was emailed to you. Select View Nonprofit Portraits, then enter Columbus Community Clinical Oncology Program and click on Search. Click on the Give Now button on the right side of the screen.

The Columbus CCOP is a 501 (c)(3) organization, and all contributions are tax deductible.

